Provention Bio Stock Forecast, Price & News

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

Is Provention Bio a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio or view top-rated stocks.

How has Provention Bio's stock price been impacted by COVID-19 (Coronavirus)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRVB stock has decreased by 47.3% and is now trading at $4.75.
View which stocks have been most impacted by COVID-19.

Are investors shorting Provention Bio?

Provention Bio saw a increase in short interest in the month of November. As of November 30th, there was short interest totaling 2,880,000 shares, an increase of 18.5% from the November 15th total of 2,430,000 shares. Based on an average trading volume of 549,700 shares, the short-interest ratio is presently 5.2 days. Approximately 5.4% of the shares of the stock are short sold.
View Provention Bio's Short Interest.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Provention Bio.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) issued its earnings results on Thursday, November, 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.08. The firm earned $0.68 million during the quarter, compared to analysts' expectations of $3.75 million. During the same period in the prior year, the company posted ($0.56) EPS.
View Provention Bio's earnings history.

What price target have analysts set for PRVB?

8 analysts have issued twelve-month price targets for Provention Bio's shares. Their forecasts range from $8.00 to $25.00. On average, they anticipate Provention Bio's share price to reach $17.75 in the next year. This suggests a possible upside of 273.7% from the stock's current price.
View analysts' price targets for Provention Bio or view top-rated stocks among Wall Street analysts.

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:

• Ashleigh W. Palmer, Chief Executive Officer & Director
• Christina Yi, Chief Operating Officer
• Thierry Chauche, Chief Financial Officer
• Francisco Leon, Chief Scientific Officer
• Eleanor Leni Ramos, Chief Medical Officer

Who are some of Provention Bio's key competitors?

Some companies that are related to Provention Bio include ADC Therapeutics (ADCT), Innoviva (INVA), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Revance Therapeutics (RVNC), PureTech Health (PRTC), Organogenesis (ORGO), Axsome Therapeutics (AXSM), Vectura Group (VEGPF), Reata Pharmaceuticals (RETA), Nurix Therapeutics (NRIX), CannTrust (CNTTF), Rani Therapeutics (RANI) and MannKind (MNKD).
View all of PRVB's competitors.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $4.75.

How much money does Provention Bio make?

Provention Bio has a market capitalization of $301.03 million. The company earns $-98.58 million in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Provention Bio have?

Provention Bio employs 59 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

Where are Provention Bio's headquarters?

Provention Bio is headquartered at P.O. BOX 666, OLDWICK NJ, 08858.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at (908) 428-9136 or via email at [email protected].